(Reuters) -There have been no reported deaths among young U.S. adults who developed a rare heart inflammation known as myocarditis after getting the Pfizer Inc/BioNTech COVID-19 vaccine, the Centers for Disease Control and Prevention said on Monday.
It is known that myocarditis occurs at a higher rate among those who contract COVID-19 than in those who have been vaccinated with the Pfizer/BioNTech vaccine or the one produced by Moderna Inc.
None of the 384 people between the ages of 16 to 29 who developed the heart condition after receiving the Pfizer/BioNTech vaccine died, the Atlanta-based health agency said at a meeting of its Advisory Committee on Immunization Practices.
It added that there were no reported cases of deaths among those in that age group who had myocarditis after receiving the Moderna shot.
The risk of myocarditis ranges from between 18.5 cases per 1 million doses after a second dose of the Pfizer/BioNTech vaccine to 20.2 per million doses after a second dose of the Moderna vaccine in those between the ages of 18 and 24, a higher risk than in other age groups. The risk was also significantly higher among males than females, according to the CDC’s data.
A total of 2,574 preliminary cases of myocarditis or pericarditis, another rare type of heart inflammation, have been reported among those who received COVID-19 vaccinations in the United States, with about half occurring in those who got the Pfizer/BioNTech vaccine, about 20% among those who got the Moderna shot and the remainder in those who got Johnson & Johnson’s vaccine.
Source: Read Full Article